4D Molecular Therapeutics (FDMT) Receivables - Other (2021 - 2022)
4D Molecular Therapeutics (FDMT) reported Receivables - Other of $700000.0 for Q4 2022, little changed year-over-year from $700000.0 in Q4 2021, and little changed quarter-over-quarter from $700000.0 in Q4 2021.
4D Molecular Therapeutics (FDMT) Receivables - Other (2021 - 2022) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 2 years of Receivables - Other data on file, last reported at $700000.0 in Q4 2022.
- Receivables - Other for Q4 2022 came in at $700000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2022 was $700000.0 (changed 0.0% YoY), and the FY2022 annual result was $700000.0, changed 0.0% from the prior year.
- Receivables - Other steadied at $700000.0 in Q4 2022 per FDMT's latest filing, from $700000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $700000.0 in Q4 2021 and troughed at $700000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 700,000.00 |
| Dec 31, 2022 | 700,000.00 |
| Dec 31, 2021 | 700,000.00 |
| Dec 31, 2021 | 700,000.00 |